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SummaRy Pemphigus vulgaris (PV) is an infrequent autoimmune bullous disease 
involving the skin and mucous membranes, which is rare in pediatrics. Although the 
main therapy for childhood PV are steroids, immunosuppressive drugs are often need-
ed to control the disease. We report the case of an 11-year-old Caucasian boy who 
presented with a 10 months history of PV unresponsive to steroids and to intravenous 
immunoglobulin. The therapeutic use of rituximab allowed a long-lasting and com-
plete remission. According to a good safe profile and to our case report, as well as the 
literature, rituximab may be considered an safe and efficacious treatment for PV.
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InTRoduCTIon
Pemphigus vulgaris (PV) is an autoimmune bul-
lous disease involving the skin and mucous mem-
branes. It is characterized by the presence of autoan-
tibodies directed against some components of the 
desmosomes, specifically desmoglein 1 and 3, lead-
ing to a loss of cell-to-cell adhesion. The mean age of 
onset is between the age of 40 and 60 years, while it 
is a rare disease in children, with few cases reported 
in literature. 
Rituximab, a chimeric anti-CD20 antibody, can be 
a valid alternative to conventional systemic therapy 
usually performed to treat this rare disease. Current-
ly, only 11 cases of childhood PV (CPV) treated with 
rituximab are reported in literature (1-7). We present 
a case of a refractory CPV successfully treated with 
rituximab.
CaSe RePoRT
An 11-year-old Caucasian boy presented with a 
10 month history of vesicular and bullous erythema-
tous skin lesions, which ruptured to form progressive 
erosions with crusting (Fig. 1). The oral mucosa also 
showed the presence of several painful erosions.
His past medical history was negative for infec-
tions, autoimmune diseases, and malignancies. Rou-
tine laboratory investigations were all negative and 
the skin cultures did not show signs of bacterial, viral, 
or fungal infections.
Before arriving in our care, the patient received a 
diagnosis of PV in another institute and was treated 
with prednisone (1.5 mg/kg per day). However, the 
patient reported only scant clinical improvement but 
developed steroidal side effects such as weight gain 
and the characteristic facies lunaris (Fig.1).
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Based on the diagnosis and the unresponsive-
ness to steroid therapy, we started treatment with 
intravenous immunoglobulin (IVIg) at 400mg/kg per 
day during three consecutive days (with intervals of 
45 days), for a total of 5 cycles. Initially, we observed 
a clinical improvement, but the patient experienced 
a recrudescence of the disease about 1 month later. 
Consequently, we decided to treat the patient with 
rituximab. The treatment started with 2 courses of 
rituximab (375mg/m2), 18 days apart. After the first 
line of rituximab, new lesions stopped appearing and 
90% of the cutaneous lesions healed within 4 weeks 
(Fig. 2). Currently, the patient attends strict follow-
up appointments, and after 10 months he does not 
presented further cutaneous lesions and has normal 
serum level of autoantibodies.
dISCuSSIon
CPV accounts for 1.4-2.9% of all PV cases (1), af-
fecting both sexes equally, and the mean age of onset 
is 12 years (2). CPV seems to have a better prognosis 
than PV, but its clinical course is extremely variable 
(1). Nevertheless, before the availability of corticoste-
roids, most patients died within 5 years of the disease 
onset (1).
CPV often arises with oral involvement that in-
cludes multiple painful vesicles and erosions. This 
pattern is frequently the only clinical feature of CPV; 
it can thus be misdiagnosed as bullous impetigo, 
staphylococcal ecthyma, or herpetic stomatitis. The 
appearance of flaccid, easily ruptured blisters and 
positive Nikolsky sign can suggest the correct diag-
nosis.
The main therapy for CPV is based on oral corti-
costeroids, but potential long term adverse effects 
limit their use. In literature, we found a lot of adjuvant 
steroids-sparing treatment, such as oral gold (3), my-
cophenolate mofetil (2), IVIg (4), methotrexate, cyclo-
phosphamide, azathioprine, and dapsone (5). Addi-
tionally, a case of CPV unresponsive to azathioprine, 
mycophenolate mofetil, plasmapheresis, and IVIG 
with systemic prednisone, successfully treated with 
rituximab, has also been reported (6).
From 2005 to date, rituximab was used in 10 CPV 
cases (1,7,8), with a good side effect profile (1). Al-
though there is no clear evidence about which ap-
proach to rituximab administration is the safest or 
the most effective in children (6), we decided to use 
rituximab based on our positive experience in adults 
(9) and on the data present in the literature.
ConCLuSIon
Based on the remarkably positive experience in 
this case and on previous reports, we believe that 
rituximab may be considered a safe and efficacious 
treatment for CPV.
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